Business
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
SAN FRANCISCO, May 18, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026.
About this update from Vir Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3057,"height":718,"url":"https://media.zenfs.com/en/business-wire.com/bb25a6a53c80a8320200bb2a8170c59b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ntrH6m3LwgZ1C3U5hoKJSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyNQ--/https://media.zenfs.com/en/business-wire.com/bb25a6a53c80a8320200bb2a8170c59b","width":960,"height":225},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/HOrRt4OLtYOQVI69TNXISw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE1MA--/https://media.zenfs.com/en/business-wire.com/bb25a6a53c80a8320200bb2a8170c59b","width":640,"height":150},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/c4ZIfDL6ImWvU2wzZOv2sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NjQ-/https://media.zenfs.com/en/business-wire.com/bb25a6a53c80a8320200bb2a8170c59b","width":1200,"height":282}},"lazy":false},{"type":"text","content":"- Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL","length":167,"tagName":"p"},{"type":"text","content":"- Poster presentation of Week 48 subgroup analysis from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for poster tour by EASL","length":142,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, May 18, 2026--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026.","length":317,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 96 endpoint results from the Phase 2 SOLSTICE trialFormat: Oral presentationSession: General Session IIPresenter: Tarik AsselahDate: May 29, 2026Time: 12:15 p.m. to 12:30 p.m. CEST","length":347,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":347,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"SOLSTICE Week 48 subgroup analysis: Impact of BMI on ALT normalization after successf...